Friday 6 November 2026 Export GILD’s income statement to Excel — free account

Gilead Sciences, Inc.

GILD Healthcare Drug Manufacturers General

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.

Revenue: +6.83%
EPS: −20.3%
Free cash flow: +21.1%
Total debt: +5.17%

Quarter to September 2026, against a year earlier

167.72 0.15 +0.09%

Follow GILD

Alert me

Market cap: $207.8B
P/E: 0.0×
Fwd P/E: −41.3×
Dividend yield: 1.94%
F-score: 8/9
Altman Z: 4.03
Beneish M: −2.45
Dividend safety: 77/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Gilead Sciences, Inc. (GILD) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Gilead Sciences, Inc. (GILD) trades at a price to free cash flow of 15.1×. Over the past ten years it has ranged from 5.1× (December 2016) to 20.5× (February 2026); the current reading is higher than 93% of that period. That is below the Drug Manufacturers General industry median of 21.3× and below the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/GILD/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Gilead Sciences, Inc. price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/GILD/metrics/price-to-free-cash-flow">Gilead Sciences, Inc. (GILD) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	16.1×	44.46%
FY2024	11.2×	(20.15%)
FY2023	14.0×	9.00%
FY2022	12.8×	52.16%
FY2021	8.4×	(13.35%)
FY2020	9.7×	(1.80%)
FY2019	9.9×	(8.66%)
FY2018	10.9×	26.80%
FY2017	8.6×	40.58%
FY2016	6.1×	(15.68%)

Period	Price to free cash flow	Change
Sep 2026	13.4×	10.72%
Jun 2026	12.1×	(28.29%)
Mar 2026	16.9×	4.79%
Dec 2025	16.1×	7.22%
43 more quarters	Free account

Against its own ten years

Low 5.1× High 20.5×

Ten-year median 10.6×

Current reading's percentile 93

Company	Price to free cash flow
SNY Sanofi compare	6.7×
BMY Bristol Myers Squibb Company compare	13.9×
GILD Gilead Sciences, Inc.	15.1×
PFE Pfizer Inc. compare	15.5×
NVS Novartis AG compare	21.7×
MRK Merck & Co., Inc. compare	22.6×
NVO Novo Nordisk A/S compare	23.5×
AMGN Amgen Inc. compare	27.3×
AZN AstraZeneca PLC compare	45.8×
Drug Manufacturers General industry median	21.3×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Gilead Sciences, Inc. (GILD) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on GILD

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on GILD

Stockrow Weekly